Giannoudis, Athina <br/><br/>
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.  [electronic resource] 

 -  Blood  Jan 2013 
 - 628-37 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2012-01-405035  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Alleles<br/>Antineoplastic Agents--pharmacokinetics<br/>Benzamides<br/>Cell Line, Tumor<br/>Female<br/>Gene Expression<br/>Gene Expression Regulation, Leukemic<br/>Genotype<br/>Humans<br/>Imatinib Mesylate<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Middle Aged<br/>Models, Molecular<br/>Organic Cation Transporter 1--chemistry<br/>Piperazines--pharmacokinetics<br/>Polymorphism, Single Nucleotide<br/>Protein Conformation<br/>Protein Kinase Inhibitors--pharmacokinetics<br/>Pyrimidines--pharmacokinetics<br/>Treatment Outcome<br/>Young Adult